CIOReview
CIOREVIEW >> Pharma & life sciences >>

A Further Stride in the IMMray PanCan-d Verification Study

By CIOReview | Tuesday, October 20, 2020

Immunovia announces positive results from the verification study, the last stride towards the launch of IMMray PanCan-d.

FREMONT, CA: Immunovia, a diagnostic company that provides highly accurate blood tests for the early identification of cancer and autoimmune diseases, announces positive results from the verification study and will now commence the validation study, the last stride towards the release of IMMray PanCan-d. The verification study analysis exhibits results in line with the previous commercial test model study (CTMS), which opens the way for the final blinded validation study.

The company is highly pleased with the verification study results and is now commencing the preparation for the validation process while finishing up some bioinformatics for all subgroups of samples. These results will be made public as fast as the study is completed in all its details. The company remains fully committed to the release of IMMray PanCan-d and are now only one step away from the Q4 start sales of IMMray  PanCan-d.

The study was conducted to verify the IMMray  PanCan-d commercial biomarker signature using samples and to further validate its accuracy in differentiating PDAC (pancreatic ductal adenocarcinoma) stages I via IV vs. controls that best mirror the clinical, commercial setting situation that is patients with non-specific but concerning symptoms. All the samples were freshly gathered through its Key Opinion Leaders (KOL) at pancreatic illnesses reference sites in the USA and Europe. The verification study precedes the last blinded validation test required for sales start.

Immunovia AB is a diagnostic firm producing and commercializing highly accurate blood tests for the early identification of cancer and autoimmune diseases based on Immunovia’s proprietary test platform called IMMray. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique disease biomarker signature.